Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04860414
Other study ID # JACQUIN 2020
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 3, 2021
Est. completion date June 17, 2021

Study information

Verified date December 2022
Source Centre Hospitalier Universitaire Dijon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Approximately 24 million people worldwide suffer from dementia, with Alzheimer's disease being the most common cause. Alzheimer's disease typically progresses in three stages: presymptomatic, prodromal ("early onset" or minor cognitive impairment) and major cognitive impairment with loss of autonomy and significant psycho-behavioral symptoms. Efforts to counteract its expansion are increasing, and there is a need for biomarkers to identify the disease in its earliest stage in order to provide prompt treatment. Faced with a episodic memory disorder, it is possible, thanks to certain criteria, highlighted by neuroimaging, or by biomarkers obtained by biological analysis of cerebrospinal fluid (during a lumbar puncture), to detect Alzheimer's disease from the prodromal stage, or even earlier. The main limitation of these criteria is their invasive nature. Other non-invasive biomarkers would therefore be useful to help diagnose Alzheimer's disease at an early stage. Gustatory evoked potentials (GEP), a technique for exploring taste sensory pathways, could meet these needs. Indeed, GEPs are a method of exploring the gustatory sensory pathway based on the recording of cerebral electrical activity by electroencephalography (EEG). It is a painless, accessible, inexpensive and non-invasive technique. The alteration of gustatory functions is present in many neurological conditions, but often takes second place to sensory or motor symptoms. Rare studies have studied taste in patients with Alzheimer's disease, but they have demonstrated, using subjective tests only, an early gustatory impairment linked to a degeneration of the gustatory cortex. It was observed that the performance of subjects with minor or major cognitive impairment was weaker than that of healthy subjects, without the patient being aware of these taste disorders. The aim of the study is to explore taste functions in patients with minor cognitive impairment, major cognitive impairment such as mild Alzheimer's disease, by comparing them to healthy subjects. For this purpose, we wish to compare the results of subjective taste tests (tasting solutions, especially salty ones, answering food preference questionnaires), parameters of taste evoked potentials recorded by electrodes stuck on the scalp and hormonal parameters obtained by blood sampling, between the three groups of subjects mentioned.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date June 17, 2021
Est. primary completion date June 17, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - A person who has given oral consent. - For patients with early stage Alzheimer's disease, both the primary caregiver and the patient will need to give oral consent. - ADULT - Body Mass Index (BMI) < 30 kg/m². - Patients meeting the diagnostic criteria for early-stage Alzheimer's disease: imaging (cerebral MRI), neuropsychobiological criteria (consultation with neuropsychological assessment, CSF biomarkers) and CDR (Clinical Dementia Rating Scale) rated at 1 or 1.5 - for the "subjects with early-stage Alzheimer's disease" group - Patients meeting the diagnostic criteria for minor cognitive impairment: imaging (brain MRI) and neuropsychological assessment with a CDR scale of 0.5 - for the group "subjects with minor cognitive impairment". - Absence of cognitive problems and normal neurological assessment - for the healthy group. - Fasting at least 2 hours before PEG measurement Exclusion Criteria: - - A person who is not affiliated to or not a beneficiary of a social security system. - Person subject to a measure of legal protection (curatorship, guardianship) - Person subject to a judicial safeguard measure - Pregnant, parturient or breastfeeding woman - Adult unable to express consent or perform cognitive testing. - Minor - No Caregiver for Mild Alzheimer's Disease Patients - Active smoker - Diabetes (type 1 or type 2) - Taking a treatment that interferes with taste - Body Mass Index (BMI) = 30 kg/m2 - MMS Score <20 - Cerebral MRI finding another cause of neurocognitive disorder (except for Fazekas 1 vascular lesions accepted). - Known COVID-19 infection

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Blood sampling
Fasting blood glucose, dosage of acylated and non-acylated ghrelin, leptin, insulin and serotonin.
Other:
Cognitive Assessment
QPC Cognitive complaint questionnaire, CDR functional autonomy scales and IADL 4 items, MMSE cognitive scores, Dubois 5-word test, clock test, BREF, Isaacs test, BARD naming battery and MADRS depression scale
Subjective taste tests
Scales of taste perceptive intensity, taste pleasure, hunger sensation (visual analogue scales from 0 to 10 cm) and food preferences on the one hand, and on the other hand, subjective tests of taste threshold determination by triangular tests of increasing sugar solution concentrations.
Objective taste tests
Recording of gustatory evoked potentials

Locations

Country Name City State
France Chu Dijon Bourgogne Dijon

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Amplitude of gustatory evoked potentials After a fasting period of 2 hours
Primary Latency of the gustatory evoked potential After a fasting period of 2 hours
See also
  Status Clinical Trial Phase
Completed NCT02554253 - The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction Phase 2
Recruiting NCT02777060 - Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures N/A
Completed NCT02342041 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects Phase 1
Recruiting NCT01659593 - Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients N/A
Completed NCT01561820 - Mild Cognitive Impairment, Buddy Supported Exercise/ My Buddy Study N/A
Completed NCT00743405 - Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects Phase 1
Completed NCT05373394 - Evaluation of Cognitive and Motor Neurological Disorders in the Short and Long Term After Surgery for the Removal of a Diffuse Low-grade Glioma of the Supplementary Motor Area
Completed NCT02324153 - Ramelteon in the Prevention of Post-operative Delirium Phase 2
Completed NCT00458094 - Peer Support for Increasing Physical Activity in People With Serious Mental Illnesses N/A
Completed NCT05486195 - A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect Phase 1
Not yet recruiting NCT03866018 - Contribution of Physical Activity to Self-esteem and Motivation in Older Adults With Minor to Major Cognitive Disorders Such as Alzheimer's Disease or Related Disorders N/A
Recruiting NCT02876536 - Effect of Transcutaneous Electrical Nerve Stimulation on Cognition in Multiple Sclerosis Patients N/A
Completed NCT02321475 - EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders
Completed NCT01881646 - Postoperative Neuroinflammation and Cognitive Dysfunction After Abdominal Surgery Phase 4
Recruiting NCT05888961 - Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials N/A
Completed NCT02575482 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects Phase 1
Completed NCT01983384 - Anesthetic Depth and Postoperative Delirium Trial - 2 N/A
Completed NCT00937846 - Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study Phase 1
Completed NCT01772095 - ADVANCE Study: Alzheimer Disease eVAluation iN Clinical PracticE N/A
Completed NCT06078332 - Remote Cognitive Multidomain Assessment in People With Cognitive Disorders